NewsBenzingaIntellia Therapeutics Completed Participant Enrollment In Its MAGNITUDE-2 Study Of ATTRv-PN Intellia Therapeutics Completed Participant Enrollment In Its MAGNITUDE-2 Study Of ATTRv-PN Benzinga 2026.11.04 13:02 (GMT+0) Open on Benzinga Other news Soluna Holdings, Inc. (SLNH) Q3 2026 Earnings Call Transcript ‘The Odds Are Almost Zero’: Scott Galloway Doesn’t See Jensen Huang Returning to Nvidia Analysis: Hyperliquid's Stock and Commodity Trading Revenue Grows 6x, Reducing Reliance on Crypto Market Grayscale: Multiple Factors Have Turned Crypto Valuations Oversold; Current Levels Are a Medium- to Long-Term Buying Opportunity for Bitcoin Bitcoin Lightning Network Developers Patch LND Flaw That Could Wipe Payment Records After Node Restart Canton Strategic Holdings Q3 Revenue of $3.05M, Net Loss Widens to $35.1M
Analysis: Hyperliquid's Stock and Commodity Trading Revenue Grows 6x, Reducing Reliance on Crypto Market
Grayscale: Multiple Factors Have Turned Crypto Valuations Oversold; Current Levels Are a Medium- to Long-Term Buying Opportunity for Bitcoin
Bitcoin Lightning Network Developers Patch LND Flaw That Could Wipe Payment Records After Node Restart